Gallium-68 DOTATATE

Drug Profile

Gallium-68 DOTATATE

Alternative Names: 68Ga-DOTA-TATE; 68Ga-DOTA-tyr3-Octreotate; DOTATATE-Ga68; GA-68 DOTATATE; GalioMedix; NETSPOT; Somakit-TATE

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advanced Accelerator Applications
  • Developer Advanced Accelerator Applications; Assistance Publique - Hopitaux de Marseille; Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Radio-Isotope Therapy of America Foundation; RadioMedix
  • Class Imaging agents; Organometallic compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuroendocrine tumours

Most Recent Events

  • 03 Aug 2016 Launched for Neuroendocrine tumours (Diagnosis) in USA (IV)
  • 02 Jun 2016 Registered for Neuroendocrine tumours (Diagnosis) in USA (IV)
  • 01 Jun 2016 Phase-II clinical trials in Neuroendocrine tumours (Diagnosis) in Canada (IV) (NCT02810600)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top